Huldrych F. Gunthard
Experienced in Kaposi Sarcoma

Huldrych F. Gunthard

Zurich, ZH, CH 
Experienced in Kaposi Sarcoma
Zurich, ZH, CH 
OverviewLocationsClinical Research

Overview

Huldrych Gunthard practices in Zurich, Switzerland. Mr. Gunthard is rated as an Experienced expert by MediFind in the treatment of Kaposi Sarcoma. His top areas of expertise are HIV/AIDS, Hepatitis, Hepatitis C, and Hepatitis D.

His clinical research consists of co-authoring 390 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Kaposi Sarcoma.

Gender
Male

Locations

Zurich, ZH, Switzerland
Other Locations
Lausanne, VD, Switzerland
Cantonal Hospital St Gallen, St Gallen, Lugano, TI, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Randomised Controlled Trials to Assess Approved SARS-CoV-2 Vaccines in Immunocompromised Patients: A Master Protocol for the Set-up of a Swiss Cohorts Based Trial Platform
Randomised Controlled Trials to Assess Approved SARS-CoV-2 Vaccines in Immunocompromised Patients: A Master Protocol for the Set-up of a Swiss Cohorts Based Trial Platform
Enrollment Status: Completed
Publish Date: January 25, 2024
Intervention Type: Biological
Study Drugs: Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine
Study Phase: Phase 3
Raltegravir Use in the Swiss HIV Cohort Study (SHCS) - Evaluation of Efficacy, Safety, Plasma Levels and Evolution of Resistance
Raltegravir Use in the Swiss HIV Cohort Study (SHCS) - Evaluation of Efficacy, Safety, Plasma Levels and Evolution of Resistance
Enrollment Status: Completed
Publish Date: June 06, 2018
Intervention Type: Drug
View 1 Less Clinical Trial

386 Total Publications

Inflammation and B cell activation define a plasma proteome signature predicting tuberculosis in people with HIV.
Inflammation and B cell activation define a plasma proteome signature predicting tuberculosis in people with HIV.
Journal: mBio
Published: August 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gunthard's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile